Results 71 to 80 of about 49,935 (237)
Objective Although Takayasu arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B cell activation and its contributions to TAK pathogenesis. Methods Histologic analysis of paravascular lymph nodes and affected arteries was conducted
Chenglong Fang +10 more
wiley +1 more source
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Aim To examine the effects of tofacitinib, an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA), on composite endpoints in patients with PsA. Method In two Phase (P)3 studies, patients had active PsA and inadequate response (IR)
Hsu, M-A +10 more
core +1 more source
Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson +127 more
wiley +1 more source
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
Background Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Heike C. Hawerkamp +6 more
doaj +1 more source
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic +7 more
wiley +1 more source
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected ...
Cutolo M +3 more
core +1 more source
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych +10 more
wiley +1 more source
Objectives The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration ≤2 years of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between early and established axSpA patients treated with biologic/targeted synthetic disease‐modifying anti ...
Annik Steimer +18 more
wiley +1 more source
Background Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a sometimes life-threatening complication in RA patients. SKG mice develop not only arthritis but also an ILD resembling RA-ILD.
Sho Sendo +4 more
doaj +1 more source
Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report
Nan Luo, Lingyuan Zhong, Nana Luo, Qiuyue Wang, Tianhao Li, Pingsheng Hao Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Pingsheng Hao; Tianhao Li, Department ...
Luo N, Hao P, Wang Q, Li T, Zhong L
core

